Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company CritiTech Inc.
DescriptionIntraperitoneally administered suspension of nanoparticulate paclitaxel
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer; Treat peritoneal neoplasms
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today